Actavis To Expand Iceland Facility

Published: 08-Feb-2010

Actavis has said that it will be expanding its manufacturing site in Iceland, whereby increasing capacity at the site by 50%. With this decision, the company also intends to create 50 new jobs.

The company's Hafnarfjordur facility in Iceland is a manufacturing site which exports 95% of its products. After expansion, the SOD-site‘s capacity will increase to 1.5 billion tablets per year, depending on the mix of products. Production is expected to start at the new facility by year end 2010, with no disruption to current manufacturing capabilities.

The site produces many of Actavis‘ latest generics and specialises in new product launches. Actavis hf in Iceland currently employs about 300 people, mostly in production and quality. By the end of this year, 50 new jobs will be created following the expansion.

The Hafnarfjordur site is ISO 14001 and OHSAS 18001 certified and runs on sustainable energy; electricity from hydropower and geothermal heating.

Actavis Group is engaged in the development, manufacture and sale of generic pharmaceuticals. The company employs over 10,000 people in 40 countries, including about 570 in Iceland.

Tell your friend about this article